Compare TG Therapeutics Inc (TGTX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tenet Healthcare Corporation — how do they compare? TG Therapeutics Inc trades at $49.74 (market cap $7.64B), while Tenet Healthcare Corporation trades at $266.42 (market cap $20.89B). The key difference: Tenet Healthcare Corporation is far larger — about 2.7× TG Therapeutics Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | THC | |
|---|---|---|
Market Cap | $7.64B | $20.89B |
Sector | Health | Health |
52-Week High | $59.06 | $262.63 |
52-Week Low | $26.94 | $161.37 |
Enterprise Value | $7.84B | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Tenet Healthcare (THC) trades at $266.15, up 2.39% today, with strong technical momentum including a golden cross formation. The stock shows robust fundamentals with a P/E of 10.03, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with EPS of $6.12 versus $4.26 estimate, driving positive analyst sentiment.
Outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target, though investors should monitor policy headwinds in healthcare and the stock's proximity to 52-week highs. The company's ambulatory growth and raised 2026 guidance support continued upside potential despite net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
